<DOC>
	<DOCNO>NCT00722358</DOCNO>
	<brief_summary>The primary purpose study assess change HCV RNA dose BMS-650032 follow-up period subject chronic hepatitis C infection</brief_summary>
	<brief_title>A Multiple Ascending Dose Study BMS-650032 HCV Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Chronically infect HCV genotype 1 Treatment naive HCV RNA viral load ≥10*5 IU/mL BMI 18 35kg/m² Women childbearing potential ( WOCBP ) Any significant acute chronic medical illness stable control medication consistent HCV infection HCV infect subject treatment nonresponder ( define subject receive least 12 week SOC continue detectable HCV RNA level subject attain 2log decline HCV RNA level 12 week stop treatment HCV infect subject treatment intolerant ( define subject unable receive least 12 week SOC due toxicity associate interferon and/or ribavirin HIV and/or HBV positive Major surgery within 4 week study drug administration gastrointestinal surgery could impact absorption study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>